Breast Cancer Clinical Trial
Official title:
A Pragmatic, Non-Interventional Study of DigiMeds™ in Combination With Standard of Care for Treatment of Patients With Cancer
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch
(patch), and a mobile app, which records time-stamped medication type and dose alongside
biometric activity.
The aim of this registry is to collect and analyze data on the use of DigiMeds™ and a digital
feedback system on medication adherence, patient-provider communication, and data-driven
optimization of therapy for cancer patients.
Patients will be prescribed the DMP and DigiMeds™ (capecitabine or supportive medications) by
their healthcare provider. The pharmacy will co-encapsulate the prescribed medication with a
sensor.
The actual doses of DigiMeds™ will be based on standard of care as prescribed by treating
physician. Patients will be instructed in the use of the DigiMeds™ and the DMP based on
standard of care plus use of the DMP system.
Every effort should be made to take the DigiMeds™ as prescribed.
Patients in this study will be given the option to use their personal smartphone or will be
provided a provisioned iPad to use for the duration of the study. Each patient will receive a
Starter Kit comprised of two wearable sensor pods, adhesive strips, and instructions.
Additionally, some kits may contain the provisional iPad Mini and charger for those without
an approved smart device. Should a device malfunction occur, such as a broken pod, the
patient can replace it with their spare pod. Broken pods should be returned to Proteus as
soon as possible and all pods must be returned to the clinic upon completion of the study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04574609 -
Evaluation of the Impact of the Use of Hypnotherapy Performed by a Virtual Reality Toolalong the Care Pathway of Patients Undergoing Breast Cancer Treatment.
|
N/A | |
| Recruiting |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
|
||
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Enrolling by invitation |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Active, not recruiting |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT04190381 -
A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy
|
N/A | |
| Recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Suspended |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02894398 -
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
|
Phase 2 | |
| Completed |
NCT01857193 -
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
|
Phase 1 |